Latest Analytical Science News

Trajan Group Holdings reports steady market demand and successful cost initiatives in H2 FY26 but warns of a $4 million revenue hit from Australian dollar appreciation.

Trajan Group Holdings reports a mixed first half for FY26 with soft Q1 performance but a strong Q2 rebound, maintaining full-year guidance amid tariff and cost pressures.

CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.

Trajan Group Holdings Limited reported a 7.4% increase in revenue to $166.5 million for FY25, marking a significant turnaround with a return to profit after tax attributable to owners of $2.2 million. The company also reduced net debt and improved EBITDA by 26.2%, driven by organic growth and strategic acquisitions.

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, exceeding guidance despite operational headwinds. However, EBITDA fell slightly short of forecasts, reflecting challenges in supply chains and market shifts.